Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25281978 | 0.88 | HCAR2 (0.34) | TSHRHCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL19342207 | 0.88 | HCAR2 (0.34) | TSHRHCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL518574 | 0.84 | — | — | |
| SCHEMBL873013 | 0.80 | TSHR (0.42) | TSHRHCAR2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL620969 | 0.80 | — | — | |
| SCHEMBL1563963 | 0.79 | ESR2 (0.50) | TSHRHCAR2ALDH1A1MAPTRECQL | |
| SCHEMBL7300563 | 0.79 | USP2 (0.41) | MAPTRECQLMEN1LMNAKMT2A | |
| SCHEMBL13210062 | 0.79 | HCAR2 (0.38) | TSHRHCAR2MEN1KMT2A | |
| SCHEMBL431512 | 0.78 | — | — | |
| SCHEMBL106091 | 0.78 | TSHR (0.41) | TSHRHCAR2KEAP1NFE2L2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441588-B2 | Methods and compositions for treating bacterial infection | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2019-10-15 | — | — | US | disclosed |
| EP-2844258-B1 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTION | UNIV MICHIGAN REGENTS (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-2881384-B1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-20180057465-A1 | Inhibitors of Necroptosis | CATALYST THERAPEUTICS PTY LTD (AU) | 2018-03-01 | — | — | US | disclosed |
| US-20180057465-A1 | Inhibitors of Necroptosis | CATALYST THERAPEUTICS PTY LTD (AU) | 2018-03-01 | — | — | US | disclosed |
| US-20180057465-A1 | Inhibitors of Necroptosis | CATALYST THERAPEUTICS PTY LTD (AU) | 2018-03-01 | — | — | US | disclosed |
| US-20180042928-A1 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTION | Nanova, Inc. | 2018-02-15 | — | — | US | disclosed |
| EP-3256452-A1 | INHIBITORS OF NECROPTOSIS | Catalyst Therapeutics Pty Ltd. (AU) | 2017-12-20 | — | — | EP | disclosed |
| US-9814719-B2 | Methods and compositions for treating bacterial infection | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170056405-A1 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTION | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2017-03-02 | — | — | US | disclosed |
| US-7125870-B2 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1651613-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | Aventis Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| EP-1648868-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | Celltech R & D Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| EP-1641771-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | Celltech R & D Limited (GB) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005014555-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2004113298-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R & D LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113312-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R & D LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
| WO-2004043349-A2 | ISOXAZOLINE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441588-B2 | Methods and compositions for treating bacterial infection | MMP8, CUTA, ELANE | TSHR 4848/4885HCAR2 1470/4885KEAP1 2239/4885 |
| US-20170056405-A1 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTION | MMP8, RHOA, EPCAM | TSHR 4852/4885HCAR2 2749/4885KEAP1 1047/4885 |
| US-20180042928-A1 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTION | MMP8, CUTA, ELANE | TSHR 4848/4885HCAR2 1470/4885KEAP1 2239/4885 |
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP2, MMP1, MMP9 | TSHR 1507/4885HCAR2 801/4885KEAP1 4061/4885 |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | P2RX3, P2RX2, P2RX5 | TSHR 1167/4885HCAR2 42/4885KEAP1 1326/4885 |
| US-20180057465-A1 | Inhibitors of Necroptosis | RIPK3, RIPK1, AIFM1 | TSHR 4108/4885HCAR2 1923/4885KEAP1 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.